Publications by authors named "P Kanellis"
Introduction: Multiple sclerosis (MS) is an immune-mediated central nervous system disorder and a growing global health challenge affecting nearly 3 million people worldwide. Incidence and prevalence continue to increase with no known cause or cure. Globally governments and non-profit organizations fund research toward better understanding of and treatments for multiple sclerosis.
View Article and Find Full Text PDFArticle Synopsis
- A prodrome refers to the early signs or symptoms of a disease that appear before the main symptoms emerge, and is recognized in various conditions like Parkinson's and type 1 diabetes.
- Recent findings suggest that multiple sclerosis (MS) also has a prodromal stage, which presents an opportunity for early intervention to potentially prevent or delay the onset of classical MS.
- There is still much to learn about the prodromal stage of MS, so more research is necessary to establish clear criteria for identifying individuals at high risk for developing MS, which could aid in future treatment trials.
COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes.
Mult Scler Relat Disord
September 2022
Women with multiple sclerosis (MS) are often of childbearing age. Thirty-six women with MS who were pregnant (n = 27) or within 6 weeks postpartum (n = 9) were reported in the North American COViMS registry and their COVID-19 outcomes were described. One pregnant and one postpartum woman were hospitalized.
View Article and Find Full Text PDFBackground: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, though results from early trials of neuroprotective agents have been mixed. The recent introduction of the term 'active' secondary progressive MS into the therapeutic lexicon has introduced potential confusion to disease description and thereby clinical management.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to understand how COVID-19 affected patients with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) using data from the COViMS Registry.
- Out of 77 NMOSD patients, a significant portion tested positive for SARS-CoV-2, with 64.9% not requiring hospitalization, while 10.4% died; having a comorbidity was linked to worse outcomes.
- In contrast, 75.0% of the 20 MOGAD patients were also positive for the virus, but none died, indicating better overall outcomes for this group despite similar medication usage.